V
Verismo Therapeutics
Developing car t-cell therapy for solid tumors
About Verismo Therapeutics
Verismo Therapeutics is at the forefront of developing advanced CAR T cell therapies aimed at treating solid tumors, a significant challenge in cancer treatment. Traditional CAR T cell therapies have struggled with solid tumors due to T cell exhaustion and ineffective tumor elimination. Verismo addresses these issues with its innovative KIR CAR platform. This next-generation technology incorporates a multi-chain immunoreceptor design, inspired by natural killer (NK) cell receptors, which helps T cells remain effective over a longer period and perform better in the challenging environments of solid tumors.
The company's primary clients are healthcare providers, including hospitals and specialized cancer treatment centers, that seek cutting-edge therapies for their patients. Verismo operates in the biotechnology and healthcare market, focusing specifically on oncology, the branch of medicine that deals with cancer.
Verismo's business model revolves around research and development (R&D) and partnerships. The company invests heavily in R&D to continuously improve its CAR T cell therapies. Revenue is generated through licensing agreements, partnerships with pharmaceutical companies, and potentially through direct sales of their therapies once they receive regulatory approval.
In summary, Verismo Therapeutics is revolutionizing cancer treatment with its unique KIR CAR platform, designed to overcome the limitations of first-generation CAR T cell therapies. By focusing on solid tumors, the company is addressing a critical unmet need in oncology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Philadelphia, United States
- Employees
- 32
- Open positions
- 4
- Dealroom signal
- 80.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Dec 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jan 2025 | $4M | — | The Institute for Follicular Lymphoma Innovation | ↗ |
| GRANT✓Other financing | Sep 2024 | $150K | — | ScaleReady | ↗ |
Growth signals
Latest recorded traffic for Verismo Therapeutics is 3.1K monthly website visits, up 72.2% over the last three months. Verismo Therapeutics's team grew 10.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
BRV Capital Management- IFIgnite Innovation Fund
Hong Leong Bank
Dongkoo Bio&Pharma
ScaleReady
The Institute for Follicular Lymphoma Innovation
Other known investors1 additional known investor
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Verismo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Verismo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.